Loading
A phase 2 trial of repotrectinib in lung cancer, run by MedSIR, now recruiting.
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis is a phase 2, interventional study registered as NCT06315010 by MedSIR, with a registry enrolment figure of 20 participants, started 2025-06-27 and due to reach its primary completion in 2027-03. Interventions recorded: Repotrectinib. Conditions listed: NSCLC; Brain Metastases; ROS1 Gene Rearrangement. Primary outcome: Intracranial Objective Response Rate (IC-ORR). Lung eligibility wording from the registry: "Histologically documented NSCLC". Sites: Austria, Germany, Spain. No results are recorded here; the registry entry is the source.
Shares ROS1-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares ROS1-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares ROS1-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.